FAQ ClinicalThought


Program Content


  • FAQs: Targeting HER3 in NSCLC
    FAQs: Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 25, 2023

    View Activity


cover img faculity

Yasushi Goto, MD, PhD

Assistant Chief 
Department of Thoracic Oncology 
National Cancer Center Hospital Japan
Tokyo, Japan 

cover img faculity

Helena Yu, MD

Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner


Supported by an educational grant from

Daiichi Sankyo, Inc.